VAXCYTE INC.
1.15
USD
(+0.88%)
04/25/2025 - 19:59
Closed 15 min delayed data - NASDAQ Stocks
| Open: | 1.11 |
| Change: | +0.01 |
| Volume: | 55,279 |
| Low: | 1.09 |
| High: | 1.18 |
| High / Low range: | 0.09 |
| Type: | Stocks |
| Ticker: | PCVX |
| ISIN: |
VAXCYTE INC. news, videos and press releases
For more news please use our advanced search feature.
VAXCYTE INC. - More news...
VAXCYTE INC. - More news...
- 03/31/2025 - 11:00 Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study
- 03/30/2025 - 21:00 Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study
- 02/25/2025 - 21:01 Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
- 02/12/2025 - 21:05 Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
- 02/05/2025 - 13:00 Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
- 01/30/2025 - 21:05 Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference
- 12/03/2024 - 13:00 Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
- 11/12/2024 - 12:30 Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
- 11/05/2024 - 21:01 Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update
- 09/11/2024 - 20:05 Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
- 09/06/2024 - 20:05 Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- 09/05/2024 - 03:58 Vaxcyte Announces Pricing of $1.3 Billion Public Offering
- 09/03/2024 - 20:01 Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
- 09/03/2024 - 11:07 Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
- 09/02/2024 - 22:40 Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
- 08/06/2024 - 20:05 Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update
- 07/02/2024 - 12:30 Vaxcyte Appoints John Furey to Board of Directors
- 05/08/2024 - 20:05 Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
- 04/02/2024 - 20:05 Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
- 03/04/2024 - 13:30 Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
- 02/27/2024 - 21:01 Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- 02/15/2024 - 21:05 Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
- 02/02/2024 - 23:39 Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- 02/01/2024 - 21:05 Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
- 01/31/2024 - 04:37 Vaxcyte Announces Pricing of $750 Million Public Offering
- 01/30/2024 - 21:01 Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
- 01/29/2024 - 13:30 Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
- 01/16/2024 - 21:01 Vaxcyte Appoints Whitney Jones as Chief People Officer
- 01/04/2024 - 21:01 Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise
- 12/04/2023 - 23:35 VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
